Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15 16/09/2025

27,39 USD (+3,28%)

(+3,28%) 16/09/2025

Grafiek Alkermes plc

Grafiek Alkermes plc

1 dag1d 3,28%
1 week1w 1,71%
1 maand1m -2,58%
3 maanden3m -7,99%
6 maanden6m -20,31%
1 jaar1j -1,26%
5 jaar5j 48,46%

Alkermes plc in het nieuws

Toon enkel gratis nieuws

12 september 2025 · Alkermes Appoints Joshua Reed as Chief Financial Officer · Persbericht

11 september 2025 · Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program · Persbericht

8 september 2025 · Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 · Persbericht

25 augustus 2025 · Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 · Persbericht

29 juli 2025 · Alkermes plc Reports Second Quarter 2025 Financial Results · Persbericht

21 juli 2025 · Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 · Persbericht

15 juli 2025 · Alkermes to Report Second Quarter Financial Results on July 29, 2025 · Persbericht

2 juni 2025 · Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference · Persbericht

2 juni 2025 · Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences · Persbericht

29 mei 2025 · Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 · Persbericht

Profiel Alkermes plc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe